reNEW enters into partnership with Novo Nordisk Foundation Cellerator

reNEW enters into partnership with the newly established Novo Nordisk Foundation Cellerator. Professor Melissa Little, CEO of reNEW and Executive Director of reNEW Copenhagen, is excited about this partnership.

“At reNEW, our research into stem cells is driving the development of new stem cell-based treatments to repair or replace specific cells or tissues,” says Professor Little.

Given our major programmes in cell and gene-modified cell therapies, the construction of the Novo Nordisk Foundation Cellerator will be a major opportunity to help move from the laboratory to the clinic. This is currently a major hurdle in the field. As such, the goals of reNEW and the Cellerator align.”

The Novo Nordisk Foundation has committed up to DKK 950 million (EUR 127 million) to establish a world-class facility for the final development steps and upscaling of cell therapies for testing in humans. The Novo Nordisk Foundation Cellerator will fill a critical gap in the Danish cell therapy ecosystem, helping to translate breakthroughs in cell therapy research into real-world treatments for people with diseases such as chronic heart failure, Parkinson’s, kidney disease, type 1 diabetes and several forms of cancer.

The facility will be located at the Technical University of Denmark (DTU) in Lyngby. It will serve public and private, national and international clients from academia, biotech and the pharmaceutical industry and is expected to be operational in 2027.

“Cell therapies have the potential to take us from treating or managing the symptoms of chronic diseases to treating the disease itself, or even curing it with a one-off procedure,” says Thomas H.R. Carlsen, CEO of the Novo Nordisk Foundation Cellerator.

Read more at: New cell therapy facility enters fight against chronic diseases – Novo Nordisk Fonden